Preservative-free triamcinolone versus purified triamcinolone preparations;Primär konservierungsmittelfreies Triamcinolon im Vergleich zu aufgereinigten Triamcinolonpräparaten

Klinische Monatsblatter fur Augenheilkunde

Volumn 228, Issue 7, 2011, Pages 626-630

  Spitzer, M S ^a   Ziemssen, F ^a   Yoruk E ^a   Bartz Schmidt, K U ^a   Schultheiss M ^a   Szurman, P ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

kenalog; retina; triamcinolone; triesence; trivaris; Volon A

Indexed keywords

CORTICOSTEROID; PRESERVATIVE; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE;

ARTICLE; DRUG LABELING; DRUG MANUFACTURE; DRUG TREATMENT FAILURE; FOOD AND DRUG ADMINISTRATION; HUMAN; IRIVINE GASS SYNDROME; OFF LABEL DRUG USE; PSEUDOPHAKIA; RETINA VEIN OCCLUSION; SYMPATHETIC OPHTHALMIA; TEMPORAL ARTERITIS; UVEITIS; VITRECTOMY;

FEMALE; HUMANS; MALE; OPHTHALMIA, SYMPATHETIC; PRESERVATIVES, PHARMACEUTICAL; RETINAL DISEASES; TRIAMCINOLONE ACETONIDE;

EID: 79960165527     PISSN: 00232165     EISSN: 14393999     Source Type: Journal    
DOI: 10.1055/s-0029-1245621     Document Type: Article

References (16)

1. Scott I U., Ip M S., VanVeldhuisen P C., SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 2009 127 1115-1128
2. Jermak C, Dellacroce J T., Heffez J et al. Triamcinolone acetonide in ocular therapeutics. Surv Ophthalmol 2007 52 503-522 (Pubitemid 47268546)
3. Dyer D, Callanan D, Bochow T et al. Clinical evaluation of the safety and efficacy of preservative-free triamcinolone (triesence [triamcinolone acetonide injectable suspension] 40mg/ml) for visualization during pars plana vitrectomy. Retina 2009 29 38-45
4. Jonas J B., Degenring R F., Kreissig I et al. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 2005 112 593-598 (Pubitemid 41108858)
5. Szurman P, Kaczmarek R, Jaissle G B. et al. Influence of different purification techniques on triamcinolone yield and particle size spectrum. Graefes Arch Clin Exp Ophthalmol 2007b 245 689-696 (Pubitemid 46951235)
6. Nelson M L., Tennant M T., Sivalingam A et al. Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina 2003 23 686-691 (Pubitemid 37315056)
7. Jonas J B. Effects of triamcinolone acetonide injections with and without preservative. Br J Ophthalmol 2007 91 1099-1101 (Pubitemid 47344870)
8. Haller J A. Intraocular steroids in the office. Retinal Physician special issue 2009 2 45-47
9. Szurman P, Kaczmarek R, Spitzer M S. et al. Differential toxic effect of dissolved triamcinolone and its crystalline deposits on cultured human retinal pigment epithelium (ARPE19) cells. Exp Eye Res 2006 83 584-592 (Pubitemid 43902780)
10. Szurman P, Sierra A, Kaczmarek R et al. Different biocompatibility of crystalline triamcinolone deposits on retinal cells in vitro and in vivo. Exp Eye Res 2007a 85 44-53 (Pubitemid 47017266)
11. FDA NDA 22 048 / 22 223. Clinical Review/Triesence www.fda.gov
12. FDA NDA 22 220. Trivaris www.fda.gov
13. FDA NDA 14 901 /S-034. Labelling request/Kenalog-40 www.fda.gov
14. Yeung C K., Chan K P., Chiang S WY et al. The toxic and stress responses of cultured human retinal pigment epithelium (ARPE19) and human glial cells (SVG) in the presence of triamcinolone. Invest Ophthalmol Vis Sci 2003 44 5293-5300 (Pubitemid 37475401)
15. Ziemssen F, Grisanti S, Bartz-Schmidt K U. et al. Off-Label Use of bevacizumab for the Treatment of Age-Related Macular Degeneration: What is the Evidence? Drugs & Aging 2009 26 295-320
16. Spitzer M S., Kaczmarek R T., Yoeruek E et al. The Distribution, Release Kinetics, and Biocompatibility of Triamcinolone Injected and Dispersed in Silicone Oil. Invest Ophthalmol Vis Sci 2009 50 2337-2343